Chapter Assessing the Performance of Personal Protective Equipment1
Schistosomiasis is the second most prevalent parasitic disease in the world. Currently, the treatment of this disease relies on a single drug, praziquantel, and due to the identification of resistant parasites, the development of new drugs is urged. The demand for the development of robust high‐thro...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
InTechOpen
2021
|
| Subjects: | |
| Online Access: | ONIX_20210602_10.5772/65778_336 |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1869521872415096832 |
|---|---|
| author | Kechagiadakis, Georgios Pirlot, Marc |
| author_browse | Kechagiadakis, Georgios Pirlot, Marc |
| author_facet | Kechagiadakis, Georgios Pirlot, Marc |
| author_sort | Kechagiadakis, Georgios |
| collection | Directory of Open Access Books |
| description | Schistosomiasis is the second most prevalent parasitic disease in the world. Currently, the treatment of this disease relies on a single drug, praziquantel, and due to the identification of resistant parasites, the development of new drugs is urged. The demand for the development of robust high‐throughput parasite screening techniques is increasing as drug discovery research in schistosomiasis gains significance. Here, we review the most common methods used for compound screening in the parasites life stages and also summarize some of the methods that have been recently developed. In addition, we reviewed the methods most commonly implemented to search for promising targets and how they have been used to validate new targets against the parasite Schistosoma mansoni. We also review some promising targets in this parasite and show the main approaches and the major advances that have been achieved by those studies. Moreover, we share our experiences in schistosomiasis drug discovery attained with our S. mansoni drug screening platform establishment. |
| format | Online |
| id | doab-20.500.12854ir-70381 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | InTechOpen |
| publisherStr | InTechOpen |
| record_format | ojs |
| spelling | doab-20.500.12854ir-703812024-04-01T14:14:57Z Chapter Assessing the Performance of Personal Protective Equipment1 Kechagiadakis, Georgios Pirlot, Marc Schistosoma mansoni, drug screening, histone‐modifying enzymes, protein kinases, inhibitors, RNA interference thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology Schistosomiasis is the second most prevalent parasitic disease in the world. Currently, the treatment of this disease relies on a single drug, praziquantel, and due to the identification of resistant parasites, the development of new drugs is urged. The demand for the development of robust high‐throughput parasite screening techniques is increasing as drug discovery research in schistosomiasis gains significance. Here, we review the most common methods used for compound screening in the parasites life stages and also summarize some of the methods that have been recently developed. In addition, we reviewed the methods most commonly implemented to search for promising targets and how they have been used to validate new targets against the parasite Schistosoma mansoni. We also review some promising targets in this parasite and show the main approaches and the major advances that have been achieved by those studies. Moreover, we share our experiences in schistosomiasis drug discovery attained with our S. mansoni drug screening platform establishment. 2021-02-10T12:58:18Z 2021-06-02T10:09:49Z 2017 chapter ONIX_20210602_10.5772/65778_336 https://library.oapen.org/handle/20.500.12657/49222 https://directory.doabooks.org/handle/20.500.12854/70381 eng open access image/jpeg image/jpeg n/a n/a https://library.oapen.org/bitstream/20.500.12657/49222/1/54088.pdf https://library.oapen.org/bitstream/20.500.12657/49222/1/54088.pdf InTechOpen 10.5772/65778 10.5772/65778 035ecc65-6737-43cf-a13a-6bdf67ce01f4 open access |
| spellingShingle | Schistosoma mansoni, drug screening, histone‐modifying enzymes, protein kinases, inhibitors, RNA interference thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology Kechagiadakis, Georgios Pirlot, Marc Chapter Assessing the Performance of Personal Protective Equipment1 |
| title | Chapter Assessing the Performance of Personal Protective Equipment1 |
| title_full | Chapter Assessing the Performance of Personal Protective Equipment1 |
| title_fullStr | Chapter Assessing the Performance of Personal Protective Equipment1 |
| title_full_unstemmed | Chapter Assessing the Performance of Personal Protective Equipment1 |
| title_short | Chapter Assessing the Performance of Personal Protective Equipment1 |
| title_sort | chapter assessing the performance of personal protective equipment1 |
| topic | Schistosoma mansoni, drug screening, histone‐modifying enzymes, protein kinases, inhibitors, RNA interference thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology |
| topic_facet | Schistosoma mansoni, drug screening, histone‐modifying enzymes, protein kinases, inhibitors, RNA interference thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology |
| url | ONIX_20210602_10.5772/65778_336 |
| work_keys_str_mv | AT kechagiadakisgeorgios chapterassessingtheperformanceofpersonalprotectiveequipment1 AT pirlotmarc chapterassessingtheperformanceofpersonalprotectiveequipment1 |